HOME >> MEDICINE >> NEWS
Emselex(R) receives positive CHMP opinion for the treatment of overactive bladder

Basel, 30th July 2004 Novartis Pharma AG announced today that the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending that the European Commission (EC) grant a Marketing Authorisation for Emselex (darifenacin hydrobromide), 7.5mg and 15mg, for the treatment of overactive bladder (OAB) in all 25 European Union (EU) countries as well as Norway and Iceland. Upon receipt of the EC approval, Novartis will be able to market Emselex throughout these countries.

"We are delighted by the CHMP's positive opinion for Emselex, to provide overactive bladder sufferers with a new safe and effective treatment option", said Jrg Reinhardt, Global Head of Development Novartis Pharma AG. "Due to its M3 selectivity, Emselex provides effective overactive bladder symptom relief while decreasing the potential risk of safety issues such as cognitive impairment or effects on cardiac function."

OAB affects almost one in six adults in Europe1. Symptoms of overactive bladder are urinary urgency (a sudden compelling desire to pass urine, which is difficult to defer) with or without urge incontinence (involuntary leakage accompanied by urgency), urinary frequency (voiding the bladder too often), and nocturia (waking at night one or more times to void the bladder).

The CHMP based its positive opinion on Emselex's comprehensive data package for OAB. The safety and efficacy of Emselex has been extensively studied in over 90 pre-clinical studies and clinical trials, involving more than 5,000 patients. Pivotal studies explored key endpoints including the reduction in the number of incontinence episodes per week, the reduction in the number of voluntary urination episodes (micturition) per day, the reduction in the episodes and severity of urgency and an increase in the average volume of urine passed per micturition.

The phase III clinical
'"/>


30-Jul-2004


Page: 1 2 3

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
(Date:7/1/2015)... ... July 01, 2015 , ... ... new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the ... DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, commercial ...
(Date:7/1/2015)... ... July 01, 2015 , ... Renowned rhinoplasty surgeon and ... 2016 Dallas Rhinoplasty Symposium . Set for March 6th - 8th, the 2016 ... participants from the basic training and fundamentals of nasal surgery through the most modern ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... leaders Lora Posey (Manager, National Sales Training and Development) and Chuck Corso (Associate ... (LTEN) Conference in Phoenix, AZ. LTEN brings together learning and development professionals from ...
(Date:7/1/2015)... ... - (PRWEB) July 01, 2015 , ... Lisa Keys, ... virtual 5K on August 15-16th (MSG Keys’ birthday) in memory of her late husband ... decorated soldier and recipient of the Bronze Star Medal, died during a Special Forces ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... author Lisa Stolzenberg, a Professor in FIU’s School of International and Public Affairs. ... 17 years who participated in the National Survey on Drug Use and Health, ...
Breaking Medicine News(10 mins):Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
(Date:7/1/2015)... it is expanding its Baltimore -based clinical studies network and is recruiting ... patient populations.  Photo - http://photos.prnewswire.com/prnh/20150630/227303 ... ... ... "Continental hosts clinical studies for physicians across all ...
(Date:7/1/2015)... 2015  BioPharmX Corporation (NYSE MKT: BPMX) today announced ... of 3,636,364 shares of its common stock at a ... has granted the underwriters a 30-day option to purchase ... the public offering price. In addition, Korea ... has agreed to purchase 1,081,081 shares of common stock ...
(Date:7/1/2015)... ZURICH , July 1, 2015 ... reorganise its Executive Board. Mr. Gert Weber ... Medico Invest AG as Chief Executive Officer (CEO) ... starting July 1 st , 2015. Mr. Weber brings ... and technological industries and has filled various executive management ...
Breaking Medicine Technology:Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
Cached News: